AI Tokens
Stock Analysis on Net

Thermo Fisher Scientific Inc. (NYSE:TMO)

Income Statement
Quarterly Data

Thermo Fisher Scientific Inc., consolidated income statement (quarterly data)

US$ in millions

Microsoft Excel
3 months ended: Sep 26, 2026 Jun 27, 2026 Mar 28, 2026 Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022 Dec 31, 2021 Oct 2, 2021 Jul 3, 2021 Apr 3, 2021
Product revenues 6,753 6,823 6,277 7,245 6,489 6,250 5,980 6,768 6,148 6,163 5,955 6,411 6,157 6,271 6,404 6,945 6,583 7,003 8,017 7,931 7,360 7,214 7,856
Service revenues 5,384 5,171 4,728 4,970 4,633 4,605 4,384 4,627 4,450 4,378 4,390 4,475 4,417 4,416 4,306 4,505 4,094 3,967 3,801 2,771 1,970 2,059 2,050
Revenues 12,137 11,994 11,005 12,215 11,122 10,855 10,364 11,395 10,598 10,541 10,345 10,886 10,574 10,687 10,710 11,450 10,677 10,970 11,818 10,702 9,330 9,273 9,906
Cost of product revenues (3,338) (3,462) (3,261) (3,722) (3,319) (3,239) (3,125) (3,334) (3,170) (3,080) (2,939) (3,339) (3,214) (3,278) (3,337) (3,682) (3,494) (3,516) (3,555) (3,617) (3,298) (3,352) (3,327)
Cost of service revenues (3,668) (3,650) (3,314) (3,482) (3,220) (3,207) (3,004) (3,239) (3,100) (3,114) (3,201) (3,154) (3,044) (3,158) (3,233) (3,162) (2,881) (2,855) (2,799) (1,831) (1,381) (1,397) (1,370)
Cost of revenues (7,006) (7,112) (6,575) (7,204) (6,539) (6,446) (6,129) (6,573) (6,270) (6,194) (6,140) (6,493) (6,258) (6,436) (6,570) (6,844) (6,375) (6,371) (6,354) (5,448) (4,679) (4,749) (4,697)
Gross profit 5,131 4,882 4,430 5,011 4,583 4,409 4,235 4,822 4,328 4,347 4,205 4,393 4,316 4,251 4,140 4,606 4,302 4,599 5,464 5,254 4,651 4,524 5,209
Selling, general and administrative expenses (2,321) (2,333) (2,181) (2,352) (2,162) (2,140) (2,078) (2,203) (2,098) (2,111) (2,183) (2,132) (2,049) (2,145) (2,119) (2,299) (2,208) (2,209) (2,277) (2,278) (2,004) (1,899) (1,826)
Research and development expenses (348) (364) (336) (357) (346) (352) (342) (374) (346) (339) (331) (327) (319) (345) (346) (391) (351) (365) (364) (392) (351) (343) (320)
Restructuring and other costs (199) (98) (50) (47) (134) (83) (99) (229) (46) (77) (28) (80) (84) (183) (112) (55) (33) (24) (2) (46) (18) (119) (14)
Operating income 2,263 2,087 1,863 2,255 1,941 1,834 1,716 2,016 1,838 1,820 1,663 1,854 1,864 1,578 1,563 1,861 1,710 2,001 2,821 2,538 2,278 2,163 3,049
Interest income 252 207 233 259 234 297 203 227 277 295 279 309 246 178 146 150 68 36 18 11 9 11 12
Interest expense (417) (401) (354) (365) (347) (404) (303) (317) (356) (354) (363) (390) (359) (326) (300) (269) (173) (148) (136) (161) (128) (122) (125)
Other income (expense) (10) 31 (8) 4 (2) (18) 4 15 (17) 4 10 (33) 14 — (46) 35 (4) 28 (163) (526) 18 (3) (183)
Income before income taxes 2,088 1,924 1,734 2,153 1,826 1,709 1,620 1,941 1,742 1,765 1,589 1,740 1,765 1,430 1,363 1,777 1,601 1,917 2,540 1,862 2,177 2,049 2,753
Provision for income taxes (352) (167) (70) (153) (207) (92) (95) (149) (99) (128) (281) (133) (53) (52) (46) (173) (31) (198) (301) (203) (271) (219) (416)
Equity in earnings (losses) of unconsolidated entities (9) (16) (8) (29) 2 1 (14) 33 (14) (84) 23 (1) (17) (16) (25) (30) (72) (51) (19) — (3) (1) —
Net income 1,727 1,741 1,656 1,971 1,621 1,618 1,511 1,825 1,629 1,553 1,331 1,606 1,695 1,362 1,292 1,574 1,498 1,668 2,220 1,659 1,903 1,829 2,337
Net (income) loss attributable to noncontrolling interests and redeemable noncontrolling interest (6) (5) (5) (7) (5) (1) (4) 4 1 (5) (3) 24 20 (1) (3) 2 (3) (4) (5) (1) (1) (1) —
Net income attributable to Thermo Fisher Scientific Inc. 1,721 1,736 1,651 1,964 1,616 1,617 1,507 1,829 1,630 1,548 1,328 1,630 1,715 1,361 1,289 1,576 1,495 1,664 2,215 1,658 1,902 1,828 2,337

Based on: 10-Q (reporting date: 2026-09-26), 10-Q (reporting date: 2026-06-27), 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-02), 10-Q (reporting date: 2021-07-03), 10-Q (reporting date: 2021-04-03).


The financial performance over the analyzed period reveals a significant structural shift in revenue composition, characterized by a decline in product-based income and a substantial expansion in service-based revenue. Total revenues exhibit a cyclical pattern, peaking in 2022, experiencing a contraction through 2023 and early 2024, and returning to growth trends by 2025 and 2026.

Revenue Composition and Trends
A divergence is observed between product and service revenue streams. Product revenues, which began at 7,856 million US dollars in April 2021, declined to a low of 5,955 million US dollars by December 2023 before partially recovering to 6,753 million US dollars by September 2026. Conversely, service revenues demonstrated consistent growth, increasing from 2,050 million US dollars in April 2021 to 5,384 million US dollars by September 2026. This suggests a strategic transition toward a recurring revenue model.
Profitability and Margin Analysis
Gross profit peaked in April 2022 at 5,464 million US dollars but faced pressure during 2023, reaching a low of 4,140 million US dollars in April 2023. A recovery phase is evident in the later periods, with gross profit rising to 5,131 million US dollars by September 2026. Operating income followed a similar trajectory, dropping from 3,049 million US dollars in April 2021 to a trough of 1,563 million US dollars in April 2023, before stabilizing and climbing back to 2,263 million US dollars by the end of the period.
Operating Expenditure and Cost Management
Selling, general and administrative expenses remained relatively stable, generally fluctuating between 1,800 million and 2,300 million US dollars. Research and development spending showed high consistency, typically ranging between 319 million and 392 million US dollars per quarter. However, restructuring and other costs introduced significant volatility, with notable spikes in July 2021, July 2023, December 2024, and September 2026, impacting short-term operating margins.
Financial Items and Net Earnings
Interest income grew substantially from 12 million US dollars in early 2021 to peaks exceeding 300 million US dollars in 2023, reflecting higher cash balances or interest rate environments. This was offset by rising interest expenses, which grew from 125 million US dollars in April 2021 to 417 million US dollars by September 2026. Net income attributable to the company mirrored the operating trend, declining from a peak of 2,337 million US dollars in April 2021 to a low of 1,289 million US dollars in April 2023, eventually recovering to 1,721 million US dollars by September 2026.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?